You just read:

Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018

News provided by

Daiichi Sankyo Company, Limited

Jun 06, 2018, 08:00 ET